Last week, we were excited to announce the nomination of our first smart GIP/GLP-1 pancreatic gene therapy lead candidate, RJVA-002, which is designed for the treatment of obesity. RJVA-002 is a ...

How will AI continue to transform drug development? What’s next for cell and gene therapy? Who will take the crown in the ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

Last week, we were excited to announce the nomination of our first smart GIP/GLP-1 pancreatic gene therapy lead candidate, RJVA-002, which is designed for the treatment of obesity. RJVA-002 is a ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

And thirdly, as a maintenance therapy following cessation of GLP-1s to prevent rebound weight gain ... included data from the ...

UBS launched its coverage of Sagimet Biosciences (NASDAQ:SGMT) with a buy recommendation and a $12 price target, calling the company an underappreciated player in the market for liver disorder, ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit's first achievement is the opening of a new Leukopak collection ...